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Introduction
The  great  cell  biologists  of  the  19th  century,  including   
Rudolph Virchow, the German physician widely known as the 
father  of  pathology,  and  the  French  physiologist  Claude   
Bernard established the pivotal idea that individual cells func-
tion autonomously, while being part of the whole organism. 
Since then, many pathological conditions including all major 
neurodegenerative diseases have traditionally been considered 
mechanistically cell autonomous, meaning that damage within 
a selective population of affected neurons alone suffices to 
produce disease.
For most neurodegenerative conditions, injury may origi-
nate either from unknown stressors in the case of sporadic dis-
ease, or from expression of a mutant gene in the familial forms. 
With the recognition that essentially all of the genes whose 
mutation causes the inherited forms of these diseases are widely 
or ubiquitously expressed, three questions are central for under-
standing disease mechanism (and for devising therapies). First, 
what  are  the  mutant-driven  toxic  mechanisms  that  mediate   
disease? Second, is disease actually driven by cell autonomous 
mechanisms as has previously been widely assumed? Third, 
what explanation is there for the selectivity in neuronal killing 
from a widely expressed mutant?
A plethora of damage: eight proposed 
mechanisms for familial ALS
Amyotrophic  lateral  sclerosis  (ALS)  is  characterized  by 
  selective, premature degeneration and death of motor neurons 
initiating in mid-adult life. The ensuing progressive paralysis   
is typically fatal within a handful of years due to respiratory 
failure. Although the majority of incidences have no apparent 
hereditary contribution, 10% of instances are dominantly   
inherited. A landmark discovery reported in 1993 initiated the 
molecular era of ALS research with identification of mutations 
in the gene encoding for superoxide dismutase 1 (SOD1) as 
causative in 20% of the inherited cases (Rosen et al., 1993). 
A major cytoplasmic antioxidant, the ubiquitously expressed 
SOD1’s normal function is to catalytically convert highly reac-
tive superoxide (oxygen with an extra electron) to either hydro-
gen peroxide or oxygen.
Mice expressing various ALS-related mutants of SOD1 
have recapitulated the fatal paralysis seen in human patients, 
and use of them has been the most important contributor to   
defining familial ALS disease mechanisms. An important initial   
realization from these efforts is that disease is caused by one or 
more acquired toxicity(ies) of the mutant proteins, rather than 
reduced superoxide dismutase activity. A universal finding is 
that a proportion of the more than 150 SOD1 mutants (Turner 
and Talbot, 2008) fails to fold properly, thus implicating accu-
mulation of misfolded SOD1 as a possible toxic contributor in 
ALS. The misfolded SOD1 forms ubiquitinated cytoplasmic   
inclusions that occur early in disease and escalate as disease 
progresses (Bruijn et al., 1997). A sobering reality, however, is 
that 16 years after the initiating discovery (Rosen et al., 1993) 
no consensus has yet emerged as to the primary toxicity of   
Selective degeneration and death of one or more classes 
of neurons is the defining feature of human neurodegen­
erative disease. Although traditionally viewed as diseases 
mainly  affecting  the  most  vulnerable  neurons,  in  most   
instances  of  inherited  disease  the  causative  genes  are 
widely—usually  ubiquitously—expressed.  Focusing  on 
amyotrophic  lateral  sclerosis  (ALS),  especially  disease 
caused  by  dominant  mutations  in  Cu/Zn  superoxide   
dismutase (SOD1), we review here the evidence that it is 
the convergence of damage developed within multiple cell 
types, including within neighboring nonneuronal support­
ing cells, which is crucial to neuronal dysfunction. Damage 
to a specific set of key partner cells as well as to vulner­
able neurons may account for the selective susceptibility of 
neuronal subtypes in many human neurodegenerative 
diseases, including Huntington’s disease (HD), Parkinson’s 
disease (PD), prion disease, the spinal cerebellar ataxias 
(SCAs), and Alzheimer’s disease (AD).
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Mutant SOD1 inhibits the proteasome. A third 
proposal for SOD1 mutant toxicity is for misfolded mutant SOD1 
inhibition of clearance of damaged proteins by the proteasome, 
the proteolysis machine for removing abnormally folded proteins 
from the cytoplasm (Fig. 1 C). In cell culture, mutant SOD1 turns 
over more rapidly than wild-type and turnover depends on prote-
asome activity (Hoffman et al., 1996). Intracellular accumula-
tions in familial or sporadic ALS patients are not immunoreactive 
for  proteasome  components  (Ii  et  al.,  1997; Watanabe  et  al., 
2001) but have been reported to contain Dorfin, a RING finger–
type E3 ubiquitin ligase. At least in some instances, Dorfin physi-
cally binds and ubiquitinates various SOD1 mutants, thereby 
enhancing their degradation, but does not affect the stability   
of wild-type SOD1 (Niwa et al., 2002). A preponderance of   
biochemical evidence from spinal cords of SOD1 mice has   
reported decreased activities of the proteasome in lumbar spinal 
cords of SOD1 mutant mice (Kabashi et al., 2004; Cheroni et al., 
2009) or after sustained expression of mutant SOD1 in a culture 
neuronal line (Urushitani et al., 2002). In this view, a vicious   
cycle  can  thus  ensue  in  which  protein  aggregation  not  only   
increases the levels of misfolded mutant SOD1 (Hoffman et al., 
1996), but also sequesters essential cellular components (includ-
ing endogenous SOD1) within the aggregates, causing further 
damage to the affected cell (Bruijn et al., 1998).
Misfolded mutant SOD1 damages mitochon-
dria. A fourth proposal is that misfolded mutant SOD1 dam-
ages mitochondria by its deposition onto the cytoplasmic face 
of the outer membrane (Fig. 1 D) of spinal cord mitochondria 
(Liu et al., 2004; Vande Velde et al., 2008). Apparent morpho-
logical  damage  to  mitochondria  is  seen  presymptomatically   
within motor neurons of some, but not all, lines of mice that   
develop  SOD1  mutant-mediated ALS. A  proportion  of  both   
dismutase-active and -inactive mutants, however, has been shown 
convincingly to be mitochondrially associated (Mattiazzi et al., 
2002; Liu et al., 2004; Vijayvergiya et al., 2005; Vande Velde   
et al., 2008). Mitochondrial association of mutant SOD1 begins 
presymptomatically (Liu et al., 2004), firmly supporting an 
important mechanistic contribution to disease initiation.
There is no uniform view of how mitochondrial function 
is affected. ATP levels have been reported to be diminished   
in symptomatic (Mattiazzi et al., 2002) and presymptomatic 
(Browne  et  al.,  2006)  mutant  spinal  cords  of  one  mouse 
model but to be unchanged in another (Damiano et al., 2006).   
Mitochondrial calcium buffering capacity was found affected   
in spinal cords of two different strains of mice and has direct 
connection to the excitotoxic hypothesis (Damiano et al., 2006). 
Mitochondrial damage seems not to be neuronally limited, but 
is also found in spinal cord astrocytes for at least one mutant 
(Cassina et al., 2008). Still untested is whether association of 
mutant SOD1 with the mitochondrial outer membrane could 
trigger  changes  in  other  functions  vital  for  mitochondrial   
homeostasis such as protein import, mitochondrial fission/fusion, 
ionic balance, or regulation of apoptosis.
Extracellular toxicity from aberrant secretion 
of mutant SOD1. A fifth proposed mechanism involves inter-
action of misfolded mutant SOD1 with components of neuro-
secretory vesicles, chromogranin A (CgA) and chromogranin B 
mutant SOD1. Instead, a plethora of toxic mechanisms have 
been proposed to mediate pathogenesis, that is, the course of 
events that underlie the progressive fatal paralysis from degen-
eration and death of motor neurons (Fig. 1).
Excitotoxicity from mishandling of glutamate. 
One of the early proposed mechanisms—observed both in SOD1 
mutant mouse models and in familial and sporadic ALS patient 
samples—is glutamate excitotoxicity, the excessive firing of 
motor neurons derived from failure to rapidly remove synaptic   
glutamate (Fig. 1 A). Overstimulation by glutamate, the neuro-
transmitter that triggers motor neurons to fire, can elicit a cas-
cade of toxic events in the postsynaptic motor neuron including 
repetitive activation of glutamate receptors and the corresponding 
increase in calcium influx, thus overriding the storage abilities   
of mitochondria and endoplasmic reticulum (ER). Contributing 
to this phenomenon is a failure to rapidly clear extracellular glu-
tamate through deficiency in the glutamate transporter EAAT2 
in the astrocytic processes that surround synapses of motor neu-
rons (Rothstein et al., 1995; Bruijn et al., 1997; Howland et al., 
2002; Yang et al., 2009a,b). Recent evidence has shown that loss 
of connectivity between upper and lower motor neurons triggers 
reduced transcription of EAAT2 through reduced expression of a 
B motif binding phosphoprotein (KBBP), the mouse homologue 
of hnRNP K, or human heterogeneous nuclear ribonucleoprotein 
K (Yang et al., 2009b). Caspase-3 activation has also been linked 
to production of a truncated form of EAAT2 in SOD1 mutant 
mouse spinal cords (Boston-Howes et al., 2006).
Mutant SOD1 causes ER stress. Mutant SOD1 
has been argued to trigger ER stress via two different pathways 
(Fig. 1 B). Mutant SOD1 aggregates were found to accumulate 
in fractions that are enriched in ER membranes in the affected 
tissues, a phenomenon that intensifies as disease progresses. 
These ER-associated SOD1 aggregates bind to the ER-luminal 
polypeptide chain binding protein (BiP) (Kikuchi et al., 2006), 
a chaperone that regulates the activation of ER stress transduc-
ers such as IRE1, PERK, and ATF6. A later study showed that 
mutant SOD1 inhibits ER-associated degradation (ERAD), the 
cell’s machinery for eliminating proteins that fail to fold prop-
erly inside the ER. The first critical step in the ERAD process is 
the retrograde transport of misfolded proteins out of the ER   
lumen into the cytosol, where they are ubiquitinated and subse-
quently degraded by the proteasome. Multiple ALS-associated 
mutants of SOD1—including dismutase-active (e.g., SOD1
G93A, 
SOD1
A4V) and -inactive (SOD1
G85R) mutants but not the wild-
type SOD1—interact with derlin-1, a transmembrane ER protein 
that is instrumental for dislocation of misfolded proteins from 
the ER to the cytosol. Binding of mutant SOD1 to Derlin-1   
inhibits ERAD and thereby generates ER stress (Nishitoh et al., 
2008), but only after disease onset, consistent with this being a 
consequence secondary to some unidentified initiating trigger. 
Nevertheless, up-regulation of ER-related genes at presymp-
tomatic stages is seen in a subset of vulnerable motor neurons   
in mice expressing either dismutase-active or -inactive mutants 
(Saxena et al., 2009). We would note that mutant SOD1 associa-
tion with the ER may interfere with synthesis of any protein, 
like EAAT2, whose synthesis and maturation are dependent on 
passage through the ER.763 Non-cell autonomy in neurodegeneration • Ilieva et al.
GTPase that controls the activation of NADPH oxidase (a   
multiprotein  membrane-associated  complex  whose  catalytic 
subunit is Nox2). A key normal role of Nox2 in phagocytic 
cells, including microglia, is to produce highly toxic extracellu-
lar superoxide, for example, in order to kill bacteria and other 
pathogens. Harraz et al. (2008) proposed that association of 
wild-type SOD1 with Rac1 participates in a tightly regulated 
mechanism that in reducing conditions activates Nox2. Mutant 
forms of SOD1 interact with Rac1 with apparent higher affinity, 
thereby locking Nox2 in its active, superoxide-producing form. 
Paradoxically, instead of its normal job of removing intracellu-
lar superoxide, mutant SOD1 may thus be responsible for driv-
ing extracellular production of superoxide (Fig. 1 F). It should 
be noted that for the proportion of Nox2 imbedded in internal 
(CgB),  which  in  turn  can  apparently  direct  the  unexpected   
cosecretion of mutant SOD1 (Urushitani et al., 2006) by motor 
neurons or astrocytes (Fig. 1 D). Extracellular mutant SOD1 in 
turn acts to damage motor neurons through activation of microg-
lia, the innate immunity cells within the spinal cord, so as to   
ultimately drive neuronal death (Zhao et al., 2009). Moreover, 
proteasome inhibition was reported to enhance aberrant se-
cretion of mutant SOD1, suggesting a cross talk between these 
two pathways.
Mutant SOD1 generates extracellular super-
oxide. A  sixth  proposed  mechanism  of  mutant  SOD1  is 
counterintuitive: mutant stimulation of excessive extracellu-
lar production of superoxide (O

2) (Harraz et al., 2008). Both 
wild-type and mutant SOD1 can associate with Rac1, a small 
Figure 1.  Proposed mechanisms of toxicity in SOD1-mediated ALS. (A) Excitotoxicity is the hyperactivation of motor neurons resulting from failure to 
rapidly remove neurotransmitter glutamate from synapses due to deficiency in the glutamate transporter EAAT2 in the neighboring astrocytes. (B) ER stress 
is induced by abnormal interactions of mutant SOD1 with ER proteins (see text for details). (C) Proteasome inhibition due to “overload” of the proteasome 
degradation pathway with ubiquitinated misfolded protein aggregates may damage astrocytes and motor neurons. (D) Mitochondrial dysfunction medi-
ated by mutant SOD1 deposition on the mitochondrial membrane provokes release of cytochrome c in motor neurons, whereas in astrocytes it leads to 
nitroxidative stress. (E) Toxic extracellular mutant SOD1 is secreted from motor neurons and astrocytes (not depicted) after interaction with components 
of neurosecretory vesicles. (F) Superoxide production from microglia or astrocytes can damage neighboring motor neurons. (G) Altered axonal transport 
including an increase in retrogradely transported stress-related proteins was reported in mutant SOD1-expressing motor neurons. (H) Synaptic vesicle 
defects such as stalling and loss from distal synapse in vulnerable motor neurons is an early event in ALS. (I) Loss of tight junction proteins within capillary 
endothelial cells results in the disruption of the blood–spinal cord barrier and the occurrence of microhemorrhages within the spinal cord well before 
disease onset.JCB • VOLUME 187 • NUMBER 6 • 2009   764
by mutant SOD1 synthesized within the pericytes or astrocytes 
that reinforce the initial endothelial cell barrier or SOD1 made 
outside of the vasculature.
Mutant SOD1 causes damage within 
multiple cell types
From  the  confusing  diversity  of  proposed  toxic  pathways, 
which is correct? And which cells develop the crucial damage 
through their own synthesis of ubiquitously expressed mutant 
SOD1? Initial efforts assumed that disease was cell autono-
mous, that is, from mutant damage solely within motor neurons. 
Accordingly, attempts were made to generate disease from selec-
tive mutant SOD1 expression only in motor neurons. Although 
these efforts did not produce disease (Pramatarova et al., 2001; 
Lino et al., 2002), a later study succeeded with mutant synthe-
sis largely restricted to neurons, using mutant SOD1 expres-
sion driven by neuron-specific Thy1.2 promoter (Jaarsma et al., 
2008). In this latter paradigm, however, even animals with the 
highest level of mutant synthesis developed disease only at 
very late ages and disease progressed slowly without reaching 
the same degree of paralysis relative to lines expressing the 
same mutant ubiquitously.
It is now clear that toxicity of mutant SOD1 is not just 
within motor neurons. Analyses of chimeric mice that were mix-
tures of normal and SOD1 mutant-expressing cells revealed that 
high expression levels of mutant SOD1 in most (Clement et al., 
2003) or all (Yamanaka et al., 2008a) motor neurons is not suffi-
cient for early onset disease, clearly implicating mutant synthesis 
by nonmotor neurons in driving disease initiation. Lentiviral re-
duction of mutant SOD1 synthesis in motor neurons—produced 
through peripheral injection—led to long-term suppression in the 
central nervous system of mutant SOD1 synthesis selectively 
within motor neurons. This transcription-mediated mutant SOD1 
suppression slowed disease onset very markedly when applied at 
a very young age, but was of no benefit at all in slowing the rate 
of disease progression after onset (Ralph et al., 2005).
Identities of cells beyond motor neurons whose mutant 
SOD1  synthesis  contributes  to  disease  has  emerged  by  cell 
type–selective excision in mice expressing transgenes flanked 
by lox sites that permit deletion by action of Cre recombinase. 
As expected, expressing Cre recombinase under two different 
promoters largely selective to motor neurons in the central ner-
vous  system  delayed  disease  onset  from  a  dismutase-active 
ALS-linked SOD1 mutant (Fig. 2), but did not alter the rate 
of progression of disease after onset (Boillée et al., 2006;   
Yamanaka et al., 2008b). Similar deletion from motor neurons 
and interneurons (by a Lhx3-driven Cre transgene) primarily 
delayed disease onset and early disease progression (Wang et 
al., 2009). Taken together, mutant SOD1 expression in motor 
neurons determines the initial timing of disease onset and early 
progression, but very surprisingly does not contribute much to 
later disease progression.
Mutant  SOD1  causes  microglial  damage, 
which  drives  rapid  ALS  progression. Mutant SOD1 
expression in cells other than the motor neurons must therefore 
be the decisive source(s) that drive disease progression after   
onset. So which cell types develop damage that contributes to the 
membranes—including newly made Nox2 transiting from the 
ER  to  the  cell  surface—Rac1  binding  would  stimulate  high   
intracellular superoxide within the Nox2-containing vesicles. 
Like  BiP  and  Derlin-1,  still  unexplained  is  why  interaction   
between Rac1 and mutant SOD1 is not detectable at presymp-
tomatic stages.
Mutant SOD1 causes axonal disorganization 
and  disrupted  transport.  A  seventh  hypothesis  for   
mutant SOD1-dependent toxicity is through interference with 
axonal  cytoskeletal  organization  and/or  inhibition  of  axonal 
transport. As the most asymmetric cells in nature, motor neu-
rons have a crucial requirement for axonal transport to deliver 
the many components synthesized in the cell bodies to axons 
and synapses. SOD1 mutants have been demonstrated to slow 
both anterograde (Williamson and Cleveland, 1999) and retro-
grade (Murakami et al., 2001; Perlson et al., 2009) routes 
months before neurodegeneration. Indeed, axonal disorganiza-
tion, especially neurofilament misaccumulation, is a hallmark 
of both sporadic and inherited forms of ALS. Mutations in neuro-
filaments are at best causes of a very small proportion of ALS, 
however (Marszalek et al., 1996). Reduction in retrograde trans-
port  by  mutation  in  dynactin,  an  activator  of  the  retrograde   
motor  cytoplasmic  dynein,  provokes  human  motor  neuron   
disease that is substantially less severe than ALS (Puls et al., 
2003), whereas mutation in dynein provokes loss of sensory 
neurons that report position (proprioception), but not motor 
neurons (Chen et al., 2007; Ilieva et al., 2008). Similar de-
creases in overall retrograde flow in SOD1 mutant axons is, 
however, accompanied by an increase in retrogradely trans-
ported stress or cell death–related proteins (Fig. 1 G) (Perlson 
et al., 2009), presumably reflecting increased production of 
such factors in the distal axons and/or synapses. Likely coupled 
to errors in delivery early in disease are apparent synaptic vesi-
cle stalling and depletion from distal synapses of vulnerable 
motor neurons (Pun et al., 2006) (Fig. 1 H). It is conceivable 
that affinity of misfolded mutant SOD1 for membranes may 
underlie these affects on synaptic vesicles and their normal 
synaptic trafficking.
Microhemorrhages  of  spinal  capillaries  from 
mutant SOD1. A final eighth proposal is that mutant SOD1 
damage within cells of the vasculature leads to leakage of toxic 
products, including iron complexes from hemoglobin, into the 
spinal cord. Indeed, microhemorrhages within the spinal cord 
that initiate well before disease onset have been seen in all mod-
els of SOD1 mutant-mediated disease in mice (Zhong et al., 
2008). This disruption of the blood–spinal cord barrier is ac-
companied by loss of components of the tight junctions (includ-
ing ZO-1, occludin, and claudin-5) between endothelial cells 
that maintain the blood–spinal cord barrier (Fig. 1 I). Indeed, 
decreased mRNA levels of ZO-1 and occludin have been found 
in lumbar spinal cords of ALS patients, compared with control 
samples, suggesting that this mechanism of toxicity is relevant 
for human disease (Henkel et al., 2009). Although efficient 
mutant SOD1 gene excision from the endothelial cells that line 
the capillaries does not affect disease course (Zhong et al., 2009), 
unresolved is how mutant SOD1 induces the loss of these tight 
junctions and whether the damage to the capillaries is mediated 765 Non-cell autonomy in neurodegeneration • Ilieva et al.
proliferation and  activation  during  SOD1  mutant-mediated 
disease (Ajami et al., 2007).
Astrocytes  expressing  mutant  SOD1  drive 
disease progression. Astrocytes are one of the most abun-
dant cell types in the adult nervous system. Closely apposed to 
motor neurons, they are responsible for supplying nutrients, 
buffering ions, recycling neurotransmitter precursors, and lim-
iting motor neuron firing through rapid recovery of synaptic 
glutamate with their glutamate transporters. Although restrict-
ing mutant SOD1 expression in astrocytes is not sufficient for 
disease (Gong et al., 2000), selective reduction of mutant SOD1 
in astrocytes (Yamanaka et al., 2008b) slowed disease progres-
sion and doubled the length of disease duration after onset (Fig. 2). 
This was accompanied by delayed microglial activation, dem-
onstrating a functional cross talk between mutant astrocytes 
and microglia.
Mutant  astrocytes  also  induce  changes  in  their  partner 
motor neurons. In cell culture experiments, normal (but not 
mutant SOD1-expressing) astrocytes induce the up-regulation of 
the glutamate receptor subunit GluR2 in neighboring (co-
cultured) motor neurons through an unidentified soluble factor(s). 
The GluR2 subunit produces receptors that are impermeable to 
Ca
2+, thereby protecting the motor neurons from excitotoxic 
damage. Mutant SOD1 expression in astrocytes abrogated their 
GluR2-regulating capacity, rendering motor neurons vulnerable 
to excitotoxicity (Van Damme et al., 2007). Activation of the   
redox-sensitive nuclear factor erythroid-2–related transcription 
factor 2 (Nrf2) in astrocytes is thought to coordinate the up-
regulation of antioxidant defenses, thereby conferring protection 
to neighboring neurons. Indeed, astrocyte-selective up-regulation 
spread  of  motor  neuron  injury?  Three  independent  studies 
reached a common conclusion: damage within mutant-expressing 
microglial  cells—the  macrophages  of  the  central  nervous 
system—is key to rapid disease progression (Fig. 2). Using a 
CD11b-Cre transgene that yields excision of “floxed” genes 
only in the myeloid lineage, selective mutant SOD1 gene exci-
sion provided the most substantial slowing of disease progres-
sion yet seen in a rodent model of inherited ALS. Survival 
after disease onset was almost tripled (Boillée et al., 2006). 
Slowed  progression  after  reduced  mutant  SOD1  synthesis   
in  microglia  was  subsequently  confirmed  by  an  analogous   
approach in a different mutant transgenic line (Wang et al., 
2009).  Similarly,  bone  marrow  transplantation  to  generate 
complete replacement of mutant SOD1-expressing microglial 
cells with nontransgenic ones did not affect disease onset, but 
slowed progression (Beers et al., 2006). Driving disease pro-
gression does not seem to require the proliferation of mutant 
microglia in response to an initial injury, as killing of about 
half of proliferating microglia did not affect the rate of pro-
gression (Gowing et al., 2008).
A controversial point has been whether microglial cells 
from the periphery enter the brain and spinal cord during dis-
ease, and if so, whether they participate in driving or ameliorat-
ing pathogenesis. Evidence in favor of both roles has emerged 
using irradiation and grafting (Kang and Rivest, 2007), but this 
outcome is likely the result of irradiation-induced disruption   
of the blood–brain barrier (Mildner et al., 2007). A complex   
experiment which used parabiosis (thereby avoiding irradia-
tion and bone marrow transplantation) found almost no con-
tribution  of  peripherally  circulating  macrophages  to  microglial 
Figure 2.  Contribution of mutant SOD1 within 
different cell types in ALS. Despite the appar-
ent selectivity for motor neurons, multiple lines 
of  evidence  indicate  that  nonneuronal  cell 
types contribute to pathogenesis and disease 
progression  in  SOD1-mediated  neurodegen-
eration. Mutant SOD1 expression in motor neu-
rons directs the onset and development of early 
disease, but does not influence its progression. 
In contrast, mutant SOD1 expression in microg-
lia or astrocytes accelerates disease progres-
sion without affecting its onset. Expression of 
a  dismutase-active  mutant  SOD1  specifically 
in Schwann cells was found to slow disease 
progression, but the role of a dismutase-inactive   
mutant  in  these  cells  has  not  been  tested. 
Mutant  SOD1  expression  within  muscle  or   
endothelial cells does not affect ALS onset or 
progression, although some reports suggest that 
muscle might be a direct target of mutant SOD1 
toxicity. Lastly, the vasculature is damaged very 
early in disease, leading to loss of tight junc-
tions between endothelial cells and microhem-
orrhages, but whether any of this is from mutant 
SOD1 within pericytes, the terminal astrocyte, or   
coming from cells outside the vasculature is not 
established. 
1(Ralph et al., 2005; Boillée et al.,   
2006;  Jaarsma  et  al.,  2008), 
2(Beers  et  al., 
2006; Boillée et al., 2006; Wang et al., 2009),   
3(Yamanaka et al., 2008b), 
4(Lobsiger et al., 
2009), 
5(Holzbaur et al., 2006; Miller et al., 
2006;  Dobrowolny  et  al.,  2008;  Towne   
et al., 2008), 
6(Zhong et al., 2009).JCB • VOLUME 187 • NUMBER 6 • 2009   766
blunted microglial proliferation, decrease in mRNA levels for 
neurotrophic factors (BDNF, GDNF, IGF-1), for EAAT2, for 
immunomodulatory IL-4, and TGF-, but increased level of pro-
inflammatory  mRNA  for  TNF-  and  especially  for  Nox2 
(100-fold!). These results demonstrate that the presence of T lym-
phocytes, through interactions with microglia and astrocytes and/
or directly with motor neurons, modifies the local environment to 
promote neuroprotection (Beers et al., 2008).
Selectivity in ALS: damage-producing 
pathways converge in different cells
The collective evidence for SOD1 mutant-mediated ALS is that 
the disease process is decidedly non-cell autonomous (Fig. 2). 
Synthesis of mutant SOD1 within motor neurons is a primary de-
terminant of driving disease onset. Mutant synthesis by other cells 
(the most directly implicated include interneurons and cells that 
comprise the blood–brain barrier) also contributes in a substantial 
way to disease initiation. Neighboring glial cells, especially the 
astrocytes and the microglia, develop mutant damage within them, 
causing them to accelerate disease progression—very markedly 
so—whereas mutant synthesis in motor neurons has little influ-
ence on progression. Schwann cells are recipients of damage, pre-
sumably  from  the  damaged  motor  axons  to  which  they  are 
partnered, and such damage is at least in part from oxidative spe-
cies  that  can  be  diminished  by  SOD1  activity  within  the 
Schwann cells.
Combining  the  contributions  from  different  cell  types 
with the diversity in proposed toxic mechanisms (Fig. 1), we 
propose an explanation for preferential toxicity to motor neu-
rons from ubiquitously expressed mutant SOD1. All of the pro-
posed mechanisms are probably contributors to pathogenesis, 
but they generate their damage within different cell types. Initi-
ating damage takes place within the motor neurons most sus-
ceptible to ALS: here it is hard to imagine that misfolded mutant 
SOD1 aberrantly aggregated onto mitochondria does not dam-
age their function and/or distribution within the motor neuron 
and its highly extended axon. Damage to one or more cell types 
of the blood–brain barrier leads to very early microhemorrhag-
ing within the spinal cord, with release of neurotoxic hemo-
globin products, that tips the balance of already damaged motor 
neurons, thereby driving disease initiation.
ER  stress  is  generated  in  motor  neurons  and  probably 
other cell types by misfolded mutant SOD1 bound to either 
Derlin-1 or BiP. This may affect many proteins that mature in 
the ER, including those contributing to synaptic vesicles. Not 
yet established is whether ER stress is also generated by mutant 
SOD1 within astrocytes, but fully consistent with this is the loss 
of the mature EAAT2 glutamate transporter, whose reduction is 
sure to enhance calcium-dependent excitotoxicity within the 
juxtaposed motor neuron. Damage to both intracellular calcium 
stores,  the  ER  and  the  mitochondria,  would  then  accelerate 
damage within the motor neurons, fueling a feed-forward mech-
anism through which mutant astrocytes promote disease pro-
gression.  Misfolded  mutant  SOD1  within  microglia—which 
become activated and migrate to initial sites of cell injury—
triggers unregulated and high production of extracellular super-
oxide, thereby enflaming the initial injury.
of Nrf2 produced significant delay in disease onset in mouse 
models  overexpressing  dismutase-active  and  -inactive  SOD1 
mutants (Vargas et al., 2008). Perhaps most importantly, cervi-
cal transplantation of lineage-restricted astrocyte precursors 
delayed progression of mutant SOD1-mediated disease after 
onset, not only reinforcing the influence of astrocytes on disease 
progression, but demonstrating the feasibility of cell replace-
ment therapies focused on astrocytes (Lepore et al., 2008).
A  cascade  of  oxidative  damage  from  motor 
axons  to  myelinating  Schwann  cells. Schwann cells 
are in intimate contact with the full length of the axons of 
lower motor neurons. The multiple wraps of myelin provide 
the electrical insulation essential for rapid signal conduction. 
(A different cell, the oligodendrocyte, has the job of myelina-
tion of upper motor axons.) After axonal damage, Schwann 
cells also participate—in concert with peripheral macrophages—
in clearing debris and in guiding the recovering axon. Selec-
tive  excision  of  a  dismutase-active  mutant  SOD1  from  a 
substantial proportion of Schwann cells (70%) (through P0-Cre–
mediated excision) yielded a highly unexpected outcome: not 
only did removal of the mutant gene fail to slow any aspect of 
disease, it generated a substantial acceleration of the late phase 
of disease (Lobsiger et al., 2009). Indeed, a retrospective look 
at disease progression in dismutase-active and -inactive SOD1 
mutants confirmed that inactive mutants uniformly generate 
more rapidly progressing disease, consistent with an amelio-
rating influence of increased dismutase activity in Schwann 
cells. These findings implicate an oxidative cascade during 
disease progression that is triggered within axon-ensheathing 
Schwann cells and that can be ameliorated by elevated dismutase 
activity (Fig. 1 D). This provocative possibility now awaits a 
direct test, which could be posed by elevating dismutase ac-
tivity selectively within Schwann cells as a means to slow dis-
ease progression.
A controversial role of mutant SOD1 damage 
within muscle. A mechanistic role for mutant SOD1 in muscle 
remains controversial. Diminished mutant synthesis by 50–60% 
in muscle (Miller et al., 2006; Towne et al., 2008) did not affect 
any aspect of mutant SOD1-mediated disease, findings inconsis-
tent with muscle cells as a direct target of mutant SOD1 toxicity 
(Fig. 2). Indeed, stimulation of myogenesis to produce chronic 
muscle  hypertrophy  (by  inhibition  of  the  inhibitory  hormone 
myostatin) provided no benefit in slowing disease (Holzbaur et al., 
2006; Miller et al., 2006). In contrast, mutant synthesis selec-
tively within skeletal muscle did provoke damage to muscle 
(Dobrowolny et al., 2008) that was reminiscent of initial damage 
seen in SOD1 mutant-mediated ALS. A resolution of the conflict-
ing views should now be undertaken by testing whether increased 
mutant synthesis in muscle can affect onset or progression in a 
SOD1 mutant mouse that generates very late disease—as in mice 
with mutant synthesis restricted to neurons (Jaarsma et al., 2008).
A protective role of T lymphocytes in mutant 
SOD1-mediated ALS. T lymphocytes appear to play a pro-
tective role in SOD1 mutant-mediated ALS. Preventing T lym-
phocyte recruitment to the spinal cord of the mutant SOD1 mouse 
(Beers et al., 2008; Chiu et al., 2008) accelerated disease progres-
sion. Lack of T lymphocytes was accompanied by a remarkably 767 Non-cell autonomy in neurodegeneration • Ilieva et al.
Additional evidence for a non–cell autonomous mechanism   
has come from chemically induced PD. MPTP (1-methyl-4-
phenyl-1,2,3,6-tetrahydropyridine)  can  induce  a  Parkinsonian 
syndrome in humans and rodents almost indistinguishable 
from  PD  (Dauer  and  Przedborski,  2003).  The  conversion 
of  MPTP  to  the  damaging  MPP
+  depends  on  monoamine   
oxidase B, an enzyme expressed predominantly by astrocytes   
(Nakamura  et  al.,  1990;  Ekblom  et  al.,  1993)  and  sero-
toninergic  neurons,  but  not  by  the  affected  dopaminergic 
neurons (Kitahama et al., 1991; Luque et al., 1995; Jahng et al., 
1997). Myeloperoxidase, an oxidant-producing enzyme, is 
expressed by the neighboring astrocytes in brains of both PD 
patients and MPTP-induced animal models, and its genetic 
knockdown increases resistance to MPTP toxicity (Choi et al., 
2005). Microglial activation precedes neurodegeneration (at 
least in animal studies) and genetic reduction of the inducible 
nitric oxide synthase expressed by microglial cells or inhibi-
tion of microglial activation (by the antibiotic minocycline) 
ameliorates dopaminergic neurodegeneration (Liberatore et al., 
1999; Wu et al., 2002). T lymphocytes were shown to have 
invaded the brain in both postmortem human PD specimens 
and in the MPTP-treated mice during the course of neuro-
degeneration (Brochard et al., 2009). Moreover, MPTP-induced 
dopaminergic cell death was markedly attenuated in the ab-
sence of mature T lymphocytes (Brochard et al., 2009). Thus, 
in  this  chemically  induced  PD  model,  converging  damage 
within astrocytes, microglia, and invading T cells, as well as 
the target neurons, creates an oxidative milieu detrimental to 
the neurons and which is probably further exacerbated by neu-
ronally restricted oxidative pathways (Teismann et al., 2003; 
Hunot et al., 2004).
Huntington’s disease. Huntington’s disease (HD) is a 
dominant, fatal, progressive disease characterized by prominent, 
age-dependent degeneration and death of striatal medium spiny 
neurons. The lesion that underlies nearly all instances of HD is 
CAG expansion within the widely expressed huntingtin gene. 
Many more cells beyond the striatum are affected, especially 
cortical pyramidal neurons, which send their axons to synapse 
on striatal neurons. Indeed, one third of total brain mass is lost by 
end-stage disease (Zoghbi and Orr, 2000).
Like the preceding diseases covered in this review, HD   
disease mechanism is non-cell autonomous and based upon 
pathological cell–cell interactions. Progressive motor deficits 
and striato-cortical neuropathology in mice have been observed 
when mutant huntingtin expression was activated (with nervous 
system–specific nestin-Cre) (Gu et al., 2007) in multiple neuro-
nal and glial cell types, including striatal medium spiny neurons, 
cortical interneurons, and cortical pyramidal neurons. Con-
versely, when Cre synthesis was restricted to cortical pyramidal 
neurons (Gu et al., 2005) or striatal medium spiny neurons (Gu 
et al., 2007), no motor deficits or cortical neuropathology were 
observed despite mutant huntingtin aggregation.
Substantial evidence also has revealed that mutant hunting-
tin damage within microglia and astrocytes are likely pathogenic 
contributors, including progressive reactive microgliosis (Sapp 
et al., 2001). The inflammatory modulator minocycline delays 
disease in mice generated by widespread expression of mutant 
How  does  this  help  with  understanding  the  basis  of   
selectivity in neuronal loss? Recognizing the contributions of 
multiple mechanisms and direct involvement of multiple cell 
types in disease initiation and progression, the selective vul-
nerability of motor neurons to toxicity from a ubiquitously   
expressed mutant can be explained by the accidental conver-
gence of the motor neuron’s own inherent functional proper-
ties and the combination of mutant damage developed within 
it and its multiple cell partners.
ALS as the tip of the iceberg: non-cell 
autonomy in neurodegenerative disease
Although our understanding of non-cell autonomy is most 
advanced for cases of SOD1-mediated familial ALS, it is 
likely that this is going to be a unifying theme in many other 
neurodegenerative  diseases  as  almost  all  of  the  causative 
proteins  are  widely  or  ubiquitously  expressed.  For  ALS, 
within the last 18 months, dominant mutations in two other 
widely expressed genes, TDP-43 (Sreedharan et al., 2008; 
Van Deerlin et al., 2008) and FUS/TLS (Kwiatkowski et al., 
2009; Vance et al., 2009), have been reported. Both of these 
new ALS-causing genes encode proteins intimately associ-
ated with RNA processing and are at least partially depleted 
from  nuclei  in  mutant-expressing  cells.  It  remains  to  be   
determined if the underlying disease mechanism is from loss 
of nuclear function, gain of one or more toxic properties, or 
both. Moreover, TDP-43 misaccumulation in motor neurons 
and astrocytes (Neumann et al., 2006; Cairns et al., 2007) is 
seen in most instances of sporadic or familial ALS, so noncell- 
autonomous disease seems likely to be a universal feature   
of ALS. The first report of a prion promoter-driven mutant   
TDP-43 mouse line has just been published (Wegorzewska   
et  al.,  2009)  and  will  assuredly  be  followed  by  further   
work assessing if the neurological phenotype described is   
mutant specific.
Parkinson’s disease and multiple system atro-
phy. A hallmark of the second most common age-related 
neurodegenerative  disease—Parkinson’s  disease  (PD)—is 
the loss of dopaminergic neurons in a brain region called the 
substantia  nigra  (for  review  see  Dauer  and  Przedborski, 
2003). Intraneuronal accumulations of -synuclein, a highly 
abundant  presynaptic  protein,  are  a  defining  pathology  of 
sporadic and many inherited instances of PD. Although most 
incidences of disease are sporadic, multiple genetic causes 
are  known  (for  review  see  Hardy  et  al.,  2009),  including 
dominant mutations in -synuclein or increased synthesis of 
normal -synuclein. Although increased intraneuronal syn-
thesis of -synuclein can damage those neurons (Masliah   
et al., 2000), elevated expression of -synuclein selectively 
within the axon-ensheathing oligodendrocytes can also in-
duce neurodegeneration of the associated neurons (Yazawa 
et al., 2005), firmly suggesting a non–cell autonomous com-
ponent to pathogenesis. Indeed, in multiple system atrophy 
(MSA), whose clinical presentation includes Parkinsonism, 
ataxia, and autonomic failure, -synuclein–containing inclu-
sions are actually more prominent in oligodendrocytes (for 
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Prion diseases. Transmissible spongiform encepha-
lopathies, including the bovine spongiform encephalopathy 
(BSE; i.e., mad cow disease), originate not just sporadically 
or through inherited mutations but notably also by an infec-
tious agent, the prion (for review see Aguzzi and Calella, 
2009). Prions consist of an aggregated form of a ubiquitously 
expressed cellular prion protein (PrP
C) (Prusiner, 1982; Basler 
et al., 1986). PrP
C expression is necessary both for toxicity 
and prion replication because mice devoid of PrP
C (Prnp
o/o) 
are resistant to infection and disease (Büeler et al., 1993).   
A cell’s susceptibility to prion toxicity depends on the localiza-
tion of PrP
C on the plasma membrane (Chesebro et al., 2005). 
Although  clinical  symptoms  of  prion  diseases  stem  from   
neuronal injury, neighboring glial cells seem to play a deci-
sive role in prion pathogenesis. Non-cell autonomy in disease 
mechanism has been shown in at least two contexts. First, for 
infection, as in the recent outbreak of bovine spongiform   
encephalopathy in Britain or the current epidemic of prion-
mediated wasting disease in American deer (Tamgüney et al., 
2009),  an  initial  noncell-autonomous  contribution  is  after   
ingestion of prions. The route of prion movement from the 
digestive system to the brain, a process called neuroinvasion, 
has been shown to generally use prion amplification in the 
huntingtin exon 1 (R6/2), accompanied by decreased accumula-
tion of microglial-derived iNOS activity (Chen et al., 2000). 
  Mutant huntingtin accumulates in astroglial nuclei of diseased 
brains, accompanied by decreased levels of the EAAT2 gluta-
mate transporter and transporter activity in HD mouse models 
(Shin et al., 2005), and mutant astrocytes increase neuronal   
vulnerability to excitotoxicity in cell culture (Shin et al., 2005).
Spinocerebellar  ataxias.  Spinocerebellar  ataxias 
(SCAs),  characterized  by  cerebellar  degeneration,  lead  to 
progressive motor incoordination (for review see Taroni and   
DiDonato, 2004). The most affected cells are the large, cerebel-
lar Purkinje neurons. Intimate nonneuronal neighbors to these 
neurons are the Bergmann glia, the cerebellum’s specialized   
astrocytes that use long finger-like processes to enwrap the huge 
dendritic trees of Purkinje cells. Mutations in at least 25 genes 
cause ataxias, 6 of which (SCA1, 2, 3, 6, 7, and 17) represent 
dominant, polyglutamine repeat expansions (polyQ). Each of 
these mutant gene products is widely expressed. The Purkinje 
neurons are killed even when they do not make the mutant 
ataxin (Garden et al., 2002) or, even more provocatively, when 
mutant ataxin is expressed only within the Bergmann glia 
(Custer et al., 2006), demonstrating a non–cell autonomous   
disease mechanism.
Figure  3.  Non–cell  autonomous  pathogenesis  in  neurodegenerative  diseases.  This  figure  summarizes  current  evidence  suggesting  the  contribution   
of apparently unaffected cell types in pathogenic mechanisms of neurodegenerative diseases, other than ALS. 
1(Choi et al., 2008; Streit et al., 2009), 
2(Nakamura et al., 1990; Ekblom et al., 1993), 
3(Liberatore et al., 1999), 
4(Yazawa et al., 2005), 
5(Shin et al., 2005), 
6(Sapp et al., 2001), 
7(Custer   
et al., 2006), 
8(Raeber et al., 1997; Jeffrey et al., 2004), 
9(Falsig et al., 2008), 
10(Prinz et al., 2004).769 Non-cell autonomy in neurodegeneration • Ilieva et al.
Selective neuronal vulnerability in 
neurodegenerative disease: the 
neighborhood matters
Disease mechanism in each of the major neurodegenerative dis-
eases we have discussed is almost assuredly non-cell autono-
mous. We propose that neuronal selectivity in each disorder can 
be most persuasively explained not by unique vulnerability to 
damage developed solely within the neurons whose loss is char-
acteristic of each disorder, but by the coincidental convergence 
of multiple disease-causing mutant gene products provoking 
damage within the vulnerable neuron and multiple neighboring 
cell types (Fig. 3). This is a very positive insight for the pros-
pects of effective therapies, as they could be envisioned by tar-
geting any of the mechanisms and cell types involved.
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